Nebenwirkungen · Zilbrysq
Zilbrysq 16.6 mg solution for injection in pre-filled syringe Zilbrysq 23 mg solution for injection in pre-filled syringe Zilbrysq 32.4 mg solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 5–6
HOS-147446 · Präparat HOS-099664
5 General disorders and Very common Injection site reactions* administration site conditions Investigations Common Lipase increased* Common Amylase increased* Uncommon Blood eosinophils increased* * See paragraph Description of selected adverse reactions. a Morphoea was reported only in long-term open-label clinical studies. The maximum duration of exposure to ZLP during the long-term clinical studies was more than 4 years.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-21T10:00:00Z · SHA-256 ed25c5c08deebf114bc9f1f656d98e3eae28bdaef6471726525eeb9d21f69716 · Passage e34fcadcce36d49262b6f780da7027f83138c8cce94ed413dba61c497307131f · Zeichen 1408–2051 im Abschnitt